MARLBOROUGH, Mass.,
May 11, 2015 /PRNewswire/ -- Boston
Scientific (NYSE: BSX) today announced that key data from 42
abstracts will be featured at the 36th Annual Scientific
Sessions of the Heart Rhythm Society (HRS)
in Boston on May 13-16.
Following recent successes – including the U.S. Food and Drug
Administration (FDA) approvals of the WATCHMAN™ Left Atrial
Appendage Closure Device and the EMBLEM™ Subcutaneous Implantable
Defibrillator (S-ICD) System, as well as the commercial roll-out of
the EMBLEM S-ICD System in Europe
and of the Rhythmia™ Mapping System in the United States – the company's planned data
presentations at HRS will underscore:
- The long-term safety and efficacy of the industry's only
Subcutaneous Implantable Defibrillator (S-ICD);
- Multiple sources of device longevity data proving the
industry-leading performance of the EnduraLife™ Battery
Technology in Boston Scientific defibrillators, as well data
highlighting premature replacement procedures due to early battery
depletion of devices without this battery technology
- The beneficial economic impact the WATCHMAN Device is projected
to have on Medicare in comparison to warfarin and aspirin for
stroke risk reduction in indicated patients with non-valvular
atrial fibrillation;
- The quality of the mapping data obtained in the initial human
experiences using the high-resolution Rhythmia Mapping System to
guide cardiac ablation procedures.
"The data presented at this meeting add substantially to the
mounting evidence, experience and successes physicians are seeing
with these novel therapies," said Kenneth
Stein, M.D., chief medical officer, Rhythm Management,
Boston Scientific. "We are pleased to continue delivering on our
commitment to help improve the care of patients with cardiac rhythm
disorders."
ABSTRACTS OF INTEREST (listed chronologically within
product categories)
Subcutaneous Implantable Defibrillator (S-ICD) Data
Presentations
- Outcomes in Patients with Congenital Heart Disease receiving
the Subcutaneous Implantable Defibrillator (S-ICD): Results from a
Pooled Analysis from the IDE Study and EFFORTLESS Registry
(PO02-204): Benjamin A. D'Souza will
present on Thursday, May 14 at
9:30 AM in the EPicenter Exhibit
Hall.
- The Patient Perspective on the entirely Subcutaneous
Implantable Defibrillator System: Early Results from the EFFORTLESS
S-ICD Quality of Life Substudy (PO03-61): Susanne S. Pedersen will present on Thursday, May 14 at 2:00
PM in the EPicenter Exhibit Hall.
- Performance of the Subcutaneous Implantable Cardioverter
Defibrillator in Primary Prevention Patients (AB28-02):
Lucas V. A. Boersma will present on
Friday, May 15 from 1:45 - 2:00 PM in Ballroom East.
- Learning Curve associated with Implantation of the totally
Subcutaneous Implantable Defibrillator: Results from a Pooled
Analysis of 882 Patients from the IDE Study and EFFORTLESS Registry
(AB26-04): Tom F. Brouwer and
Reinoud E. Knops will present on Friday, May
15 from 2:15 - 2:30 PM in Room 210B.
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and
Implantable Defibrillator (ICD) Data Presentations
- Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients
undergoing Device Replacement (PO02-40): Francesco Zanon will present on Thursday, May 14 at 9:30
AM in the EPicenter Exhibit Hall.
- Large Capacity LiMnO2 Batteries extended CRT-D Longevity in
Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6
Years (PO04-42): Ernest Lau will
present on Friday, May 15 at
9:30 AM in the EPicenter Exhibit
Hall.
- Patient Activity following Implantable
Cardioverter-Defibrillator Implantation: The ALTITUDE Activity
Study (AB27-01): Daniel Kramer will
present on Friday, May 15 from
1:30 - 1:45 PM in Room 210C.
- Projected Number of Replacements Required During Natural
Lifespan of CRT-D/ICD Recipients by Age at First Implantation for
Different Device Longevity (PO06-26): Ernest Lau will present on Saturday, May 16 at 9:30
AM in the Grand Ballroom Foyer, Level 3.
- Comparison of Advisory and Non-Advisory ICD Leads Using a Novel
Lead Alert (PO06-38): Brian Powell
will present on Saturday, May 16 at
9:30 a.m. in the EPicenter Exhibit
Hall.
WATCHMAN Device Data Presentations
- Medicare Budget Implications of Three Stroke Risk Reduction
Strategies in Non-valvular Atrial Fibrillation: Left Atrial
Appendage Closure versus Warfarin versus Aspirin (PO01-41):
Ken Stein and Stacey Amorosi will present at 6 p.m. on Wednesday, May
13 in the EPicenter Exhibit Hall.
Electrophysiology Data Presentations
- Rhythmia Mapping System: Feasibility, Safety and Short-Term
Efficacy in Left Atrial Procedures: The Initial Multicenter
Experience in the U.S. (PO03-89): Elad
Anter will present on Thursday, May
14 at 2:00 p.m.
- The Use of a New Rapid High-Resolution Mapping System to Assess
Conduction Block and Precise Location of Gaps on Linear Lesions -
Initial Experience in Human (AB32-01): Lilian Mantziari and
Tom Wong will present on
Friday, May 15 from 1:30-1:45 PM in Room 254A.
All programs are listed in Eastern Time and will take place at
the Boston Convention & Exhibition Center unless otherwise
noted. For more information, visit Boston Scientific at booth
#929.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For
more information, visit www.bostonscientific.com and connect on
Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans, our products, data presentations and
impact of data. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Media:
Trish Backes
Boston Scientific Corporation
651-582-5887 (office)
Trish.Backes@bsci.com
Investors:
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2015-300080704.html
SOURCE Boston Scientific Corporation